MX2021014447A - Metodos de otoproteccion contra agentes antineoplasicos a base de platino. - Google Patents

Metodos de otoproteccion contra agentes antineoplasicos a base de platino.

Info

Publication number
MX2021014447A
MX2021014447A MX2021014447A MX2021014447A MX2021014447A MX 2021014447 A MX2021014447 A MX 2021014447A MX 2021014447 A MX2021014447 A MX 2021014447A MX 2021014447 A MX2021014447 A MX 2021014447A MX 2021014447 A MX2021014447 A MX 2021014447A
Authority
MX
Mexico
Prior art keywords
otoprotection
methods
platinum
antineoplastic agents
based antineoplastic
Prior art date
Application number
MX2021014447A
Other languages
English (en)
Inventor
John Lee
Fuxin Shi
John R Soglia
Qi-Ying Hu
Original Assignee
Decibel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/427,567 external-priority patent/US10813947B1/en
Application filed by Decibel Therapeutics Inc filed Critical Decibel Therapeutics Inc
Publication of MX2021014447A publication Critical patent/MX2021014447A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se describen métodos para la otoprotección contra agentes antineoplásicos a base de platino al administrar una sal de tiosulfato a un sujeto que lo necesita. Normalmente, la sal de tiosulfato se administra al sujeto que tiene programado recibir un agente antineoplásico a base de platino dentro de 4 horas. De manera alternativa, la sal de tiosulfato se administra dentro de 7 horas después de la administración de un agente neoplásico a base de platino.
MX2021014447A 2019-05-31 2020-05-29 Metodos de otoproteccion contra agentes antineoplasicos a base de platino. MX2021014447A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/427,567 US10813947B1 (en) 2019-05-31 2019-05-31 Methods of otoprotection against platinum-based antineoplastic agents
US201962886865P 2019-08-14 2019-08-14
PCT/US2020/035271 WO2020243536A1 (en) 2019-05-31 2020-05-29 Methods of otoprotection against platinum-based antineoplastic agents

Publications (1)

Publication Number Publication Date
MX2021014447A true MX2021014447A (es) 2022-02-11

Family

ID=73553934

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014447A MX2021014447A (es) 2019-05-31 2020-05-29 Metodos de otoproteccion contra agentes antineoplasicos a base de platino.

Country Status (11)

Country Link
EP (1) EP3975722A4 (es)
JP (1) JP2022534617A (es)
KR (1) KR20220047217A (es)
CN (1) CN114302647A (es)
AU (1) AU2020284122A1 (es)
BR (1) BR112021023684A2 (es)
CA (1) CA3142153A1 (es)
IL (1) IL288532A (es)
MX (1) MX2021014447A (es)
SG (1) SG11202113053RA (es)
WO (1) WO2020243536A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0811175D0 (en) * 2008-06-18 2008-07-23 Prendergast Patrick T Anti-tumour compositions and methods
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
DK2451435T4 (da) * 2009-07-08 2022-02-28 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Natriumthiosulfat-indeholdende farmaceutiske sammensætninger
US10596190B2 (en) * 2017-11-29 2020-03-24 Oregon Health & Science University Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy
EP3986423A1 (en) * 2019-06-19 2022-04-27 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Sodium thiosulfate gel for preventing or reducing hearing loss

Also Published As

Publication number Publication date
CA3142153A1 (en) 2020-12-03
WO2020243536A1 (en) 2020-12-03
EP3975722A1 (en) 2022-04-06
BR112021023684A2 (pt) 2022-04-12
JP2022534617A (ja) 2022-08-02
KR20220047217A (ko) 2022-04-15
SG11202113053RA (en) 2021-12-30
CN114302647A (zh) 2022-04-08
IL288532A (en) 2022-01-01
AU2020284122A1 (en) 2021-12-23
EP3975722A4 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
PH12021550302A1 (en) Methods for the administration of certain vmat2 inhibitors
NZ714963A (en) Compositions and methods for treating anemia
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
MX2023010063A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo.
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
MX2020014000A (es) Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas.
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
PH12021550047A1 (en) USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS
ZA202006072B (en) Ret inhibitor for use in treating cancer having a ret alteration
MX2022006533A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo.
MX2022000143A (es) Metodos novedosos.
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
MX2021012824A (es) Métodos para tratar el prurito.
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
MX2023007579A (es) Derivado de borato y usos del mismo.
MX2020013076A (es) Compuestos de acido ascorbico y quinona en combinacion con un agente antiparasitario para el tratamiento de una enfermedad parasitaria.
MX2021014447A (es) Metodos de otoproteccion contra agentes antineoplasicos a base de platino.
MX2022005766A (es) Compuestos y métodos para la preparación de compuestos moduladores de esfingosina 1-fosfato tipo 1 (s1p1).
MX2021014523A (es) Metodos para tratar colangiocarcinoma.
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
ZA202107580B (en) Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4- methoxybenzylsulphone with enhanced stability and bioavailability
MX2021001349A (es) Un nuevo tratamiento medico para la inflamacion patologica.